Author:
Lee Yong-Seok,Silva Alcino J.
Publisher
Springer Berlin Heidelberg
Reference80 articles.
1. Acosta MT, Kardel PG, Walsh KS, Rosenbaum KN, Gioia GA, Packer RJ (2011) Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol 45:241–245
2. Alfieri P, Cesarini L, Mallardi M, Piccini G, Caciolo C et al (2011) Long term memory profile of disorders associated with dysregulation of the RAS-MAPK signaling cascade. Behav Genet 41:423–429
3. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR et al (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10:849–857
4. Araki T, Chan G, Newbigging S, Morikawa L, Bronson RT, Neel BG (2009) Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci USA 106:4736–4741
5. Aron AM, Rubenstein AE, Wallace SA, Halperin JC (1990) Learning disabilities in neurofibromatosis. In: Rubenstein AE, Korf BR (eds) Neurofibromatosis: a handbook for patients, families and healthcare professionals. Thieme, New York, pp 55–58